United States: These 42 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GLEOLAN is a drug marketed by Nxdc.

The generic ingredient in GLEOLAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2024
Generic Entry Controlled by: United States Patent Patent 7,947,295

ILEVRO is a drug marketed by

The generic ingredient in ILEVRO is nepafenac. Three suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: bremelanotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYLEESI (AUTOINJECTOR) is a drug marketed by

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. Three suppliers are listed for this generic product. Additional details are available on the bremelanotide acetate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRIPTODUR KIT is a drug marketed by

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Three suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: l-glutamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ENDARI is a drug marketed by

The generic ingredient in ENDARI is l-glutamine. Three suppliers are listed for this generic product. Additional details are available on the l-glutamine profile page.

Generic name: dalbavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DALVANCE is a drug marketed by

The generic ingredient in DALVANCE is dalbavancin hydrochloride. Three suppliers are listed for this generic product. Additional details are available on the dalbavancin hydrochloride profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KIMYRSA is a drug marketed by

The generic ingredient in KIMYRSA is oritavancin diphosphate. Three suppliers are listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ORBACTIV is a drug marketed by

The generic ingredient in ORBACTIV is oritavancin diphosphate. Three suppliers are listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

Generic name: lanreotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SOMATULINE DEPOT is a drug marketed by

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. Three suppliers are listed for this generic product. Additional details are available on the lanreotide acetate profile page.

Generic name: granisetron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: United States Patent Patent 8,715,710

SUSTOL is a drug marketed by

The generic ingredient in SUSTOL is granisetron. Three suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

Generic name: ziconotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 01, 2024
Generic Entry Controlled by: United States Patent Patent 5,364,842

PRIALT is a drug marketed by

The generic ingredient in PRIALT is ziconotide acetate. Three suppliers are listed for this generic product. Additional details are available on the ziconotide acetate profile page.

Generic name: ascorbic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ASCOR is a drug marketed by

The generic ingredient in ASCOR is ascorbic acid. Three suppliers are listed for this generic product. Additional details are available on the ascorbic acid profile page.

Generic name: levalbuterol tartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 08, 2024
Generic Entry Controlled by: United States Patent Patent 7,256,310

XOPENEX HFA is a drug marketed by

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. Three suppliers are listed for this generic product. Additional details are available on the levalbuterol tartrate profile page.

Generic name: fluorodopa f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 10, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

FLUORODOPA F18 is a drug marketed by

The generic ingredient in FLUORODOPA F18 is fluorodopa f-18. Three suppliers are listed for this generic product. Additional details are available on the fluorodopa f-18 profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BYETTA is a drug marketed by

The generic ingredient in BYETTA is exenatide synthetic. Three suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: air polymer-type a
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXEM FOAM KIT is a drug marketed by

The generic ingredient in EXEM FOAM KIT is air polymer-type a. Three suppliers are listed for this generic product. Additional details are available on the air polymer-type a profile page.

Generic name: istradefylline
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2024
Generic Entry Controlled by: United States Patent Patent 7,541,363

NOURIANZ is a drug marketed by

The generic ingredient in NOURIANZ is istradefylline. Three suppliers are listed for this generic product. Additional details are available on the istradefylline profile page.

Generic name: macimorelin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MACRILEN is a drug marketed by

The generic ingredient in MACRILEN is macimorelin acetate. Three suppliers are listed for this generic product. Additional details are available on the macimorelin acetate profile page.

Generic name: mometasone furoate; olopatadine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 13, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RYALTRIS is a drug marketed by

The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. Three suppliers are listed for this generic product. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.

Generic name: granisetron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 22, 2025
Generic Entry Controlled by: United States Patent Patent 7,608,282

SANCUSO is a drug marketed by

The generic ingredient in SANCUSO is granisetron. Three suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

Generic name: aclidinium bromide; formoterol fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

DUAKLIR PRESSAIR is a drug marketed by

The generic ingredient in DUAKLIR PRESSAIR is aclidinium bromide; formoterol fumarate. Three suppliers are listed for this generic product. Additional details are available on the aclidinium bromide; formoterol fumarate profile page.

Generic name: aclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: United States Patent Patent RE46417

TUDORZA PRESSAIR is a drug marketed by

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. Three suppliers are listed for this generic product. Additional details are available on the aclidinium bromide profile page.

Generic name: lactitol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 12, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIZENSY is a drug marketed by

The generic ingredient in PIZENSY is lactitol. Three suppliers are listed for this generic product. Additional details are available on the lactitol profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 14, 2025
Generic Entry Controlled by: United States Patent Patent 10,947,544

IZERVAY is a drug marketed by

The generic ingredient in IZERVAY is avacincaptad pegol sodium. Three suppliers are listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: ixabepilone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: United States Patent Patent 7,312,237

IXEMPRA KIT is a drug marketed by

The generic ingredient in IXEMPRA KIT is ixabepilone. Three suppliers are listed for this generic product. Additional details are available on the ixabepilone profile page.

Generic name: amisulpride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BARHEMSYS is a drug marketed by

The generic ingredient in BARHEMSYS is amisulpride. Three suppliers are listed for this generic product. Additional details are available on the amisulpride profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: United States Patent Patent 7,157,456

XARELTO is a drug marketed by

The generic ingredient in XARELTO is rivaroxaban. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: United States Patent Patent 8,618,135

JUXTAPID is a drug marketed by

The generic ingredient in JUXTAPID is lomitapide mesylate. Three suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

Generic name: fish oil; medium chain triglycerides; olive oil; soybean oil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SMOFLIPID 20% is a drug marketed by

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. Three suppliers are listed for this generic product. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.

Generic name: dextroamphetamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

XELSTRYM is a drug marketed by

The generic ingredient in XELSTRYM is dextroamphetamine. Three suppliers are listed for this generic product. Additional details are available on the dextroamphetamine profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TLANDO is a drug marketed by

The generic ingredient in TLANDO is testosterone undecanoate. Three suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2025
Generic Entry Controlled by: United States Patent Patent 9,522,919

TARGINIQ is a drug marketed by

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. Three suppliers are listed for this generic product. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: United States Patent Patent 9,415,053

XARELTO is a drug marketed by

The generic ingredient in XARELTO is rivaroxaban. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: fluoroestradiol f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

CERIANNA is a drug marketed by

The generic ingredient in CERIANNA is fluoroestradiol f-18. Three suppliers are listed for this generic product. Additional details are available on the fluoroestradiol f-18 profile page.

Generic name: pralatrexate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2025
Generic Entry Controlled by: United States Patent Patent 8,299,078

FOLOTYN is a drug marketed by

The generic ingredient in FOLOTYN is pralatrexate. Three suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.

Generic name: alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ABLYSINOL is a drug marketed by

The generic ingredient in ABLYSINOL is alcohol. Three suppliers are listed for this generic product. Additional details are available on the alcohol profile page.

Generic name: phentermine hydrochloride; topiramate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

QSYMIA is a drug marketed by

The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. Three suppliers are listed for this generic product. Additional details are available on the phentermine hydrochloride; topiramate profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: United States Patent Patent 7,994,364

NUCYNTA ER is a drug marketed by

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. Three suppliers are listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: naltrexone hydrochloride; oxycodone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 03, 2025
Generic Entry Controlled by: United States Patent Patent 8,685,443

TROXYCA ER is a drug marketed by

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. Three suppliers are listed for this generic product. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

Generic name: tafenoquine succinate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KRINTAFEL is a drug marketed by

The generic ingredient in KRINTAFEL is tafenoquine succinate. Three suppliers are listed for this generic product. Additional details are available on the tafenoquine succinate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 27, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KYZATREX is a drug marketed by

The generic ingredient in KYZATREX is testosterone undecanoate. Three suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: fish oil triglycerides
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 27, 2025
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

OMEGAVEN is a drug marketed by

The generic ingredient in OMEGAVEN is fish oil triglycerides. Three suppliers are listed for this generic product. Additional details are available on the fish oil triglycerides profile page.